NASDAQ:BLTE Belite Bio (BLTE) Stock Price, News & Analysis → What’s Pelosi Buying Now? (From Altimetry) (Ad) Free BLTE Stock Alerts $48.76 -0.09 (-0.18%) (As of 06/4/2024 ET) Add Compare Share Share Today's Range$47.82▼$48.8050-Day Range$32.33▼$48.9552-Week Range$11.00▼$49.16Volume49,736 shsAverage Volume55,095 shsMarket Capitalization$1.45 billionP/E RatioN/ADividend YieldN/APrice Target$44.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Belite Bio alerts: Email Address Belite Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside8.1% Downside$44.83 Price TargetShort InterestHealthy0.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.08) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.31 out of 5 starsMedical Sector879th out of 905 stocksPharmaceutical Preparations Industry419th out of 427 stocks 1.5 Analyst's Opinion Consensus RatingBelite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBelite Bio has only been the subject of 3 research reports in the past 90 days.Read more about Belite Bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.12% of the outstanding shares of Belite Bio have been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Belite Bio has recently increased by 87.30%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBelite Bio does not currently pay a dividend.Dividend GrowthBelite Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLTE. Previous Next 1.8 News and Social Media Coverage News SentimentBelite Bio has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Belite Bio this week, compared to 2 articles on an average week.Search Interest1 people have searched for BLTE on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Belite Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Belite Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.53% of the stock of Belite Bio is held by institutions.Read more about Belite Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Belite Bio are expected to grow in the coming year, from ($1.08) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Belite Bio is -41.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Belite Bio is -41.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBelite Bio has a P/B Ratio of 14.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Belite Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Belite Bio Stock (NASDAQ:BLTE)Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Read More BLTE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLTE Stock News HeadlinesMay 27, 2024 | americanbankingnews.comBelite Bio, Inc (NASDAQ:BLTE) Given Average Recommendation of "Buy" by BrokeragesMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Belite Bio, Inc. on Strong Clinical Trials and Solid Financial FootingMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Belite Bio, Inc. ADR on Strong Financials and Promising Stargardt Disease Drug ProspectsMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Belite Bio, Inc. ADR on Promising Tinlarebant Trials and Potential Stargardt Disease TreatmentMay 14, 2024 | seekingalpha.comBelite Bio, Inc 2024 Q1 - Results - Earnings Call PresentationMay 14, 2024 | finance.yahoo.comBelite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor ConferenceMay 14, 2024 | investorplace.comBLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024May 14, 2024 | globenewswire.comBelite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor ConferenceMay 14, 2024 | finanznachrichten.deBelite Bio, Inc: Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | globenewswire.comBelite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | globenewswire.comBelite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 8, 2024 | globenewswire.comBelite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comBelite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On TinlarebantMay 6, 2024 | globenewswire.comBelite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual MeetingMay 2, 2024 | seekingalpha.comBLTE Belite Bio, IncMay 1, 2024 | globenewswire.comBelite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual MeetingApril 27, 2024 | investing.comBelite Bio secures $25 million in registered direct offeringApril 25, 2024 | globenewswire.comBelite Bio Announces $25 Million Registered Direct OfferingApril 13, 2024 | morningstar.comBelite Bio Inc ADRMarch 23, 2024 | finanznachrichten.deBelite Bio, Inc: Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in JapanMarch 22, 2024 | msn.comBelite Retreats On Start Of Clinical TrialMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed on Belite Bio as Tinlarebant Shows Promising Clinical Advancements and Market PotentialMarch 22, 2024 | globenewswire.comBelite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in JapanMarch 21, 2024 | markets.businessinsider.comBuy Rating Justified for Belite Bio, Inc. ADR Amidst Promising DRAGON Trial Progress and Strong FinancialsMarch 20, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn SituationSee More Headlines Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today6/04/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BLTE CUSIPN/A CIK1889109 Webbelitebio.com Phone858-246-6240FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$44.83 High Stock Price Target$60.00 Low Stock Price Target$25.00 Potential Upside/Downside-8.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.15% Return on Assets-41.53% Debt Debt-to-Equity RatioN/A Current Ratio24.76 Quick Ratio24.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book14.87Miscellaneous Outstanding Shares29,790,000Free Float25,834,000Market Cap$1.45 billion OptionableNot Optionable Beta-1.43 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Yu-Hsin Lin M.B.A. (Age 45)Ph.D., Chairman of the Board of Directors & CEO Mr. Hao-Yuan Chuang C.F.A. (Age 39)F.R.M., M.B.A., CFO & Director Dr. Nathan L. Mata Ph.D. (Age 57)Chief Scientific Officer Key CompetitorsOrganon & Co.NYSE:OGNBridgeBio PharmaNASDAQ:BBIOGrifolsNASDAQ:GRFSCytokineticsNASDAQ:CYTKApellis PharmaceuticalsNASDAQ:APLSView All Competitors BLTE Stock Analysis - Frequently Asked Questions Should I buy or sell Belite Bio stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLTE shares. View BLTE analyst ratings or view top-rated stocks. What is Belite Bio's stock price target for 2024? 7 Wall Street analysts have issued 12 month target prices for Belite Bio's shares. Their BLTE share price targets range from $25.00 to $60.00. On average, they anticipate the company's share price to reach $44.83 in the next year. This suggests that the stock has a possible downside of 8.1%. View analysts price targets for BLTE or view top-rated stocks among Wall Street analysts. How have BLTE shares performed in 2024? Belite Bio's stock was trading at $45.75 on January 1st, 2024. Since then, BLTE stock has increased by 6.6% and is now trading at $48.76. View the best growth stocks for 2024 here. Are investors shorting Belite Bio? Belite Bio saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 35,400 shares, an increase of 87.3% from the April 30th total of 18,900 shares. Based on an average daily trading volume, of 40,100 shares, the short-interest ratio is presently 0.9 days. View Belite Bio's Short Interest. When is Belite Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our BLTE earnings forecast. How were Belite Bio's earnings last quarter? Belite Bio, Inc (NASDAQ:BLTE) issued its quarterly earnings data on Monday, March, 11th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.11. When did Belite Bio IPO? Belite Bio (BLTE) raised $36 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share. How do I buy shares of Belite Bio? Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLTE) was last updated on 6/5/2024 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club| SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals| Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC| SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry| SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media| SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press| SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.